GEDi Cube, Renovaro Biosciences Announce Intention to Merge

Image Credit: Adobe Stock Images/Orange Square

GEDi Cube, an artificial intelligence (AI) company, and Renovaro Biosciences, a pre-clinical biotechnology organization, have revealed an exclusive letter of intent to merge into a single entity. As part of a potential merger, the focus would be on accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases.

"We are rapidly expanding our technologies to include other cancers and diseases," said Craig Rhodes, CEO, GEDi Cube, in a company press release. "I believe that uniting with Renovaro BioSciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”

Reference: AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer. Business Wire. August 9, 2023. Accessed August 10, 2023. https://www.businesswire.com/news/home/20230809952021/en/AI-Company-GEDi-Cube-and-Renovaro-Biosciences-Announce-a-Binding-Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-Cancer